Faruqi & Faruqi Investigates Inovio Investor Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy INO?
Source: PRnewswire
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Inovio Pharmaceuticals for potential claims related to investor losses incurred between October 10, 2023, and December 26, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly via phone at 877-247-4292 or 212-983-9330, aiming to assist them in understanding their legal options.
- Class Action Reminder: The firm reminds investors that April 7, 2026, is the deadline to seek lead plaintiff status in the federal securities class action filed against Inovio, underscoring the importance of timely action for affected parties.
- Potential Claim Risks: As the investigation progresses, the potential claim risks facing Inovio could impact the company's reputation and future stock price, reflecting market concerns regarding the company's compliance and governance practices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.790
Low
3.00
Averages
7.33
High
13.00
Current: 1.790
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Potential Claims Against Inovio
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals due to possible false statements made during securities transactions from October 10, 2023, to December 26, 2025, which may have harmed investors' rights.
- FDA Review Update: Although Inovio submitted its Biologics License Application for INO-3107 on December 29, 2025, the FDA indicated that insufficient information was provided to justify accelerated approval, posing regulatory challenges that could delay product launches.
- Significant Stock Decline: Following the FDA announcement, Inovio's stock plummeted by 24.45% to close at $1.73 per share, reflecting a pessimistic market outlook on the company's future prospects, which may further erode investor confidence.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply as lead plaintiff in the class action lawsuit, emphasizing the importance of seeking legal support to protect their rights.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this area.
- Investor Guidance: Investors are advised to select counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the U.S. District Court for the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the FDA submission for INO-3107, severely undermining investor confidence.
- Stock Price Volatility: Following the release of its Q2 2024 financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share, reflecting market concerns over its regulatory prospects and exacerbating investor anxiety.
- FDA Review Impact: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 application on a standard review timeline rather than an accelerated one, causing a 24.45% drop in stock price to $1.73 per share, highlighting significant regulatory challenges and their implications for the company's future commercial outlook.
See More
Reminder of Class Action Lawsuits for Shareholders of Multiple Companies
- Class Action Notification: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging shareholders to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that BlackRock failed to timely disclose investment valuation issues from November 2024 to January 2026, leading to investor misunderstandings about the company's business prospects, which could undermine shareholder confidence and affect stock prices.
- Oracle Lawsuit Impact: Oracle faces a class action from June to December 2025, claiming its AI infrastructure strategy resulted in significant capital expenditure increases without corresponding revenue growth, potentially jeopardizing its debt and credit rating, thereby impacting investor confidence.
- Paysafe and Inovio Overview: Paysafe's lawsuit highlights undisclosed high-risk client issues that may limit revenue growth, while Inovio's manufacturing deficiencies could delay FDA submissions, both posing significant negative implications for future company performance.
See More
Inovio Pharmaceuticals Accused of Misleading Investors in Class Action
- Class Action Initiated: Robbins LLP reminds all stockholders who purchased Inovio Pharmaceuticals (NASDAQ:INO) securities between October 10, 2023, and December 26, 2025, that a class action has been filed to protect investor rights and seek compensation.
- Regulatory Issues Exposed: The lawsuit alleges that Inovio misled investors regarding deficiencies in the manufacturing of its CELLECTRA device, which hindered the timely submission of the INO-3107 Biologics License Application (BLA) to the FDA, potentially overstating its regulatory and commercial prospects and impacting investor confidence.
- Stock Price Volatility: Following the Q2 2024 financial results announcement on August 8, 2024, Inovio's stock fell 3.1% to $8.44 per share due to the delay in BLA submission to mid-2025; on December 29, 2025, the stock plummeted 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated review.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by April 7, 2026; Robbins LLP offers contingency fee representation, ensuring shareholders can recover losses without upfront costs.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for filing a lead plaintiff motion to protect their legal rights.
- False Statements Allegations: The lawsuit claims that Inovio's management failed to disclose manufacturing deficiencies in its CELLECTRA device, making it unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024, which misled investors.
- FDA Review Outcome: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but stated that the company did not provide adequate information to justify eligibility for accelerated approval, leading to investor misjudgment regarding the product's regulatory and commercial prospects.
- Significant Stock Drop: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future prospects and resulting in substantial investor losses.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals due to possible false statements made during securities transactions from October 10, 2023, to December 26, 2025, which may have harmed investors' rights.
- FDA Review Update: Although Inovio submitted its Biologics License Application for INO-3107 on December 29, 2025, the FDA indicated that insufficient information was provided to justify accelerated approval, posing regulatory challenges that could delay product launches.
- Significant Stock Decline: Following the FDA announcement, Inovio's stock plummeted by 24.45% to close at $1.73 per share, reflecting a pessimistic market outlook on the company's future prospects, which may further erode investor confidence.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply as lead plaintiff in the class action lawsuit, emphasizing the importance of seeking legal support to protect their rights.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this area.
- Investor Guidance: Investors are advised to select counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the U.S. District Court for the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the FDA submission for INO-3107, severely undermining investor confidence.
- Stock Price Volatility: Following the release of its Q2 2024 financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share, reflecting market concerns over its regulatory prospects and exacerbating investor anxiety.
- FDA Review Impact: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 application on a standard review timeline rather than an accelerated one, causing a 24.45% drop in stock price to $1.73 per share, highlighting significant regulatory challenges and their implications for the company's future commercial outlook.
See More
Reminder of Class Action Lawsuits for Shareholders of Multiple Companies
- Class Action Notification: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging shareholders to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that BlackRock failed to timely disclose investment valuation issues from November 2024 to January 2026, leading to investor misunderstandings about the company's business prospects, which could undermine shareholder confidence and affect stock prices.
- Oracle Lawsuit Impact: Oracle faces a class action from June to December 2025, claiming its AI infrastructure strategy resulted in significant capital expenditure increases without corresponding revenue growth, potentially jeopardizing its debt and credit rating, thereby impacting investor confidence.
- Paysafe and Inovio Overview: Paysafe's lawsuit highlights undisclosed high-risk client issues that may limit revenue growth, while Inovio's manufacturing deficiencies could delay FDA submissions, both posing significant negative implications for future company performance.
See More
Inovio Pharmaceuticals Accused of Misleading Investors in Class Action
- Class Action Initiated: Robbins LLP reminds all stockholders who purchased Inovio Pharmaceuticals (NASDAQ:INO) securities between October 10, 2023, and December 26, 2025, that a class action has been filed to protect investor rights and seek compensation.
- Regulatory Issues Exposed: The lawsuit alleges that Inovio misled investors regarding deficiencies in the manufacturing of its CELLECTRA device, which hindered the timely submission of the INO-3107 Biologics License Application (BLA) to the FDA, potentially overstating its regulatory and commercial prospects and impacting investor confidence.
- Stock Price Volatility: Following the Q2 2024 financial results announcement on August 8, 2024, Inovio's stock fell 3.1% to $8.44 per share due to the delay in BLA submission to mid-2025; on December 29, 2025, the stock plummeted 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated review.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by April 7, 2026; Robbins LLP offers contingency fee representation, ensuring shareholders can recover losses without upfront costs.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for filing a lead plaintiff motion to protect their legal rights.
- False Statements Allegations: The lawsuit claims that Inovio's management failed to disclose manufacturing deficiencies in its CELLECTRA device, making it unlikely to submit the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024, which misled investors.
- FDA Review Outcome: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but stated that the company did not provide adequate information to justify eligibility for accelerated approval, leading to investor misjudgment regarding the product's regulatory and commercial prospects.
- Significant Stock Drop: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future prospects and resulting in substantial investor losses.
See More
